Issiaka Moctar, Zrikem Khalil, Mchachi Adil, Benhmidoune Leila, Rachid Rayad, Belhadji Mohamed El, Salam Youssoufou Souley Abdoul, Amza Abdou
Adult Ophthalmology Department, 20 August 1953 Hospital, Ibn Rochd University Hospital of Casablanca, Casablanca, Morocco.
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Adv Ophthalmol Pract Res. 2022 Oct 15;3(1):23-28. doi: 10.1016/j.aopr.2022.10.003. eCollection 2023 Feb-Mar.
Description of safety and efficacy of micropulse Transscleral cyclophotocoagulation as a treatment option for refractory glaucoma.
This is a prospective study including 39 eyes of 31 patients followed for refractory glaucoma, who benefited from transscleral cyclophotocoagulation using a microplused laser. The main indication for the procedure was increased ocular pressure refractory to quadritherapy in various types of glaucoma. The patients were treated using iridex Cyclo G6 laser with a Micropulse P3 infrared probe with a wavelength of 810 nm. The parameters for the procedure were a duration of 90 s per hemisphere with a power of 2000 mW and an energy of 180 J. Both the upper and lower hemispheres were treated in the same procedure, sparing the 3 o'clock and 9 o'clock meridians, and all the patients benefited from a single treatment session. The following parameters were evaluated: ocular pain and overall tolerance; visual acuity; and the evolution of IOP postoperatively up to 9 months.
The glaucoma subtypes treated are as follows: primary open-angle glaucoma (n = 05), chronic angle-closure glaucoma (n = 13), neovascular glaucoma (n = 07), aphakic glaucoma (n = 06), malignant glaucoma (n = 04), post-traumatic angle recession (n = 02), and inflammatory glaucoma (n = 02). The mean pre-operative intraocular pressure was 42.3 ± 5.2 mmHg and the mean post-operative intraocular pressure at 9 months was 16.9 ± 1.9 mmHg. The reduction in IOP was 49.9%. The average number of intraocular pressure-lowering medications used prior to surgery was four, and the average number of medications used at the 9-month post-operative visit was 2.0 ± 1.2 (70.3% of patients were on dual therapy). The overall success rate was 60.5%.
Micropulse transscleral cyclophotocoagulation appears to be a safe and efficient treatment for refractory glaucoma. Its indications should therefore be broadened and proposed early in various situations.
描述微脉冲经巩膜睫状体光凝术作为难治性青光眼治疗选择的安全性和有效性。
这是一项前瞻性研究,纳入31例难治性青光眼患者的39只眼,这些患者接受了使用微脉冲激光的经巩膜睫状体光凝术治疗。该手术的主要适应证是各种类型青光眼经四联疗法后眼压仍升高。患者使用Iridex Cyclo G6激光及波长为810nm的微脉冲P3红外探头进行治疗。手术参数为每半球持续90秒,功率2000mW,能量180J。上下半球在同一次手术中治疗,避开3点和9点子午线,所有患者均接受单次治疗。评估以下参数:眼痛和总体耐受性;视力;以及术后9个月内眼压的变化情况。
所治疗的青光眼亚型如下:原发性开角型青光眼(n = 05)、慢性闭角型青光眼(n = 13)、新生血管性青光眼(n = 07)、无晶状体性青光眼(n = 06)、恶性青光眼(n = 04)、外伤性房角后退(n = 02)和炎症性青光眼(n = 02)。术前平均眼压为42.3±5.2mmHg,术后9个月平均眼压为16.9±1.9mmHg。眼压降低了49.9%。术前使用降眼压药物的平均数量为4种,术后9个月随访时使用药物的平均数量为2.0±1.2种(70.3%的患者接受双联治疗)。总体成功率为60.5%。
微脉冲经巩膜睫状体光凝术似乎是一种治疗难治性青光眼的安全有效的方法。因此,其适应证应扩大,并在各种情况下尽早应用。